NCT01389973 / 2011-000554-31: A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid |
|
|
| Completed | 2 | 20 | US, Canada | ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo | Janssen Research & Development, LLC | Primary Biliary Cirrhosis | 06/13 | 06/13 | | |
